This article originally appeared in the Harvard Business Review and was co-authored by XSeed Capital Partner, Robert Siegel, co-founder and CEO of Box, Aaron Levie, and general manager of SAP.io, Maxwell Wessel.
When most of the great companies of the industrial era were founded, even the most brilliant economists believed deeply in the law
Read More
XSeed Capital is very excited to announce our investment in Narrative, a platform that enables buyers and sellers of raw data events to come together and transact.
As more people, more companies, and more devices connect over the Internet, the engagement and interactions of those constituents creates overwhelming amounts of data. At the same time, organizations are deploying
Read More
This article was written by XSeed Capital Partner, Jeff Thermond, and originally appeared on Forbes.
A noticeable fraction of the thousands of startups I have looked at in the last seven years have made attacking a societal evil (e.g., hunger, homelessness, etc) a key part of why they exist. This is extremely laudable from a
Read More
We are extremely excited to announce that Lex Machina has been acquired by LexisNexis of the RELX Group (NYSE:RELX). XSeed could not be happier for the management team and employees who built a company that is enabling lawyers and corporations to use data analytics to figure out how to make business decisions in ways that were previously impossible to do.
Read More
This XSeed blog was written by Venture Partner, Jeff Thermond, and originally appeared on Forbes.
I have seen several recent startup pitches covering different markets, having different technologies, and built with teams of differing calibers, all of which shared one unfortunate trait: The founders’ funding plans looked a lot like a Bridge to Nowhere.
Read More
One of our goals at XSeed is to invest in entrepreneurs who pursue risky, paradigm changing ideas to solve big problems that seem intractable using established approaches. Rapid, cost-effective diagnosis and data-guided treatment of antibiotic resistant diseases is one such problem – causing about 25,000 deaths and over 2 million illnesses a year in the U.S. alone, with new,
Read More
This XSeed blog was written by XSeed Capital Partner, Robert Siegel, and originally appeared on VentureBeat.
At XSeed Capital we are introduced to over 500+ new startup opportunities every year, and we directly meet or talk to 150–200 of these companies. In this context, I am sometimes asked what is the “biggest mistake” that a
Read More
XSeed Capital is thrilled with the acquisition of CirroSecure by Palo Alto Networks (PANW), which was announced today by both companies. When we first met co-founders Vikrant Karvir and Nishant Doshi 18 months ago, we were extremely impressed with their understanding of the security landscape and their strategy to differentiate in a crowded market segment. CirroSecure’s tenacious focus
Read More
This XSeed blog was written by Venture Partner, Jeff Thermond, and originally appeared on VentureBeat.
You are running your first startup. You are starting to build your team and gain customer traction. You have taken advantage of a wealth of blogs about the right hygiene for starting and building a company. It is starting to
Read More
This XSeed blog was written by Partner, Alan Chiu, and originally appeared on VentureBeat.
At XSeed Capital, we invest in seed-stage startups that are often still searching for the right product-market fit. As they start to see the tantalizing evidence of something compelling, they need to decide what to include in the product, and, just
Read More